First Republic Investment Management Inc. reduced its holdings in shares of Eli Lilly and Co (NYSE:LLY) by 0.6% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 428,535 shares of the company’s stock after selling 2,744 shares during the period. First Republic Investment Management Inc.’s holdings in Eli Lilly and were worth $36,194,000 as of its most recent filing with the SEC.
A number of other institutional investors have also modified their holdings of the business. BSW Wealth Partners lifted its stake in shares of Eli Lilly and by 0.6% in the 2nd quarter. BSW Wealth Partners now owns 4,774 shares of the company’s stock worth $393,000 after acquiring an additional 27 shares during the period. Candriam Luxembourg S.C.A. lifted its stake in shares of Eli Lilly and by 166.7% in the 3rd quarter. Candriam Luxembourg S.C.A. now owns 430,424 shares of the company’s stock worth $36,818,000 after acquiring an additional 269,038 shares during the period. Chevy Chase Trust Holdings Inc. lifted its stake in shares of Eli Lilly and by 1.0% in the third quarter. Chevy Chase Trust Holdings Inc. now owns 851,985 shares of the company’s stock valued at $72,879,000 after purchasing an additional 8,328 shares during the period. Acrospire Investment Management LLC lifted its stake in shares of Eli Lilly and by 16.7% in the second quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock valued at $115,000 after purchasing an additional 200 shares during the period. Finally, BARING ASSET MANAGEMENT Ltd lifted its stake in shares of Eli Lilly and by 114.6% in the third quarter. BARING ASSET MANAGEMENT Ltd now owns 43,492 shares of the company’s stock valued at $3,721,000 after purchasing an additional 23,229 shares during the period. 75.71% of the stock is currently owned by institutional investors.
LLY has been the subject of several recent analyst reports. Jefferies Group set a $100.00 price objective on shares of Eli Lilly and and gave the company a “buy” rating in a research note on Tuesday, January 16th. Argus upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and raised their price objective for the company from $85.52 to $115.00 in a research note on Friday, January 5th. Berenberg Bank reiterated a “buy” rating and issued a $98.00 price objective on shares of Eli Lilly and in a research note on Thursday, October 26th. Zacks Investment Research upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $95.00 price objective for the company in a research note on Thursday, October 26th. Finally, Morgan Stanley raised their price objective on shares of Eli Lilly and from $86.00 to $90.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 21st. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have given a buy rating to the company’s stock. Eli Lilly and presently has a consensus rating of “Hold” and an average price target of $93.22.
In other Eli Lilly and news, insider Donald A. Zakrowski sold 900 shares of Eli Lilly and stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $81.09, for a total transaction of $72,981.00. Following the completion of the transaction, the insider now owns 4,130 shares in the company, valued at $334,901.70. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Jeffrey N. Simmons sold 9,625 shares of Eli Lilly and stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $81.12, for a total transaction of $780,780.00. Following the transaction, the senior vice president now owns 152,120 shares of the company’s stock, valued at approximately $12,339,974.40. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 259,610 shares of company stock valued at $22,727,406. 0.20% of the stock is currently owned by company insiders.
Eli Lilly and Co (NYSE:LLY) opened at $77.55 on Thursday. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66. The stock has a market cap of $84,963.62, a PE ratio of -387.73, a price-to-earnings-growth ratio of 1.45 and a beta of 0.23. Eli Lilly and Co has a 52-week low of $73.69 and a 52-week high of $89.09.
Eli Lilly and (NYSE:LLY) last announced its earnings results on Wednesday, January 31st. The company reported $1.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.08 by $0.06. The company had revenue of $6.16 billion during the quarter, compared to analysts’ expectations of $5.93 billion. Eli Lilly and had a negative net margin of 0.89% and a positive return on equity of 31.44%. The firm’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.95 earnings per share. equities analysts expect that Eli Lilly and Co will post 4.87 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, March 9th. Shareholders of record on Thursday, February 15th will be given a dividend of $0.5625 per share. The ex-dividend date of this dividend is Wednesday, February 14th. This represents a $2.25 dividend on an annualized basis and a yield of 2.90%. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.52. Eli Lilly and’s payout ratio is presently -1,124.94%.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://ledgergazette.com/2018/02/22/first-republic-investment-management-inc-lowers-holdings-in-eli-lilly-and-co-lly.html.
Eli Lilly and Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.